Welcome to AntoXa Corporation’s newsroom.
For media inquiries, please contact:
Stacey Curry Gunn
Director of Communications
[email protected]
519.827.1131
See below for links to the latest AntoXa news.
AntoXa and SwiftPharma to present plant-made anti-ricin antibody technology to NATO expert panel
GUELPH, Ont., Canada, August 14, 2024 — AntoXa Corporation, a Canadian biopharmaceutical company developing medical countermeasures against biological and chemical agents, and Belgium-based SwiftPharma have been invited to present to the NATO Biological Defense Medical Expert Panel (BIO DEF MED) on Sept. 19 in Tournai, Belgium. The BIO DEF MED ...
New Patent for AntoXa’s Plant-Made Anti-Ricin Antibody Manufacturing Process
GUELPH, Ont., Canada, January 30, 2024 — The Canadian Intellectual Property Office has allowed a patent application for a plant-based manufacturing process to produce an antibody for treatment of ricin exposure, developed by AntoXa Corporation under license from Defence Research & Development Canada (DRDC). Canadian Patent Application No. 3,045,161, “Production ...
AntoXa Corporation and SwiftPharma Sign Exclusive Collaboration Agreement to Support the Development and Commercialization of a Plant-Made Antibody Against Ricin Exposure
GHENT, Belgium and TORONTO, Canada, September 5, 2023 – AntoXa Corporation, a Canadian biopharmaceutical company developing medical countermeasures against biological and chemical agents that might be used in terrorist attacks, and SwiftPharma, a leading innovator in the research & development of recombinant proteins derived from a proprietary plant-based production system, ...
U.S. Patent Granted for Made-in-Canada Ricin Antibody Technology
GUELPH, Ont., CANADA, Feb. 27, 2023 — The U.S. Patent Office has granted a patent for a plant-based manufacturing process to produce an antibody for treatment of ricin exposure, an outcome of research and development by AntoXa Corporation under contract with Defence Research & Development Canada (DRDC), an Agency of ...
AntoXa Corporation awarded contract extension with federal government to develop plant-made protein for potential coronavirus therapy
DRDC-funded project aims to develop recombinant human angiotensin-converting enzyme 2 (ACE2) as a potential drug candidate for COVID-19 GUELPH, Ontario, Canada, August 17, 2021 — Canadian biopharmaceutical company AntoXa Corporation has been awarded a contract extension from the Government of Canada that includes development of plant-made recombinant human angiotensin-converting enzyme ...
